Intel stock extends gains after report of possible U.S. government stake
CAMBRIDGE, Mass. - MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotech company with a market capitalization of $11.75 million, has extended the duration of its Phase 1 clinical trial for its obesity treatment candidate DA-1726 from four to eight weeks, the company announced Wednesday. According to InvestingPro analysis, the company’s shares have declined over 84% in the past year, though analysts maintain optimistic price targets ranging from $3 to $21.
The biotechnology firm has administered a fifth weekly dose to the first patient in the 48 mg multiple ascending dose cohort. The extension is designed to assess longer-term early efficacy, patient safety, and tolerability with extended exposure to the drug. While MetaVia maintains a strong current ratio of 1.55 and holds more cash than debt, InvestingPro data indicates the company is rapidly burning through its cash reserves.
DA-1726 is a dual oxyntomodulin analog that targets both glucagon-like peptide-1 receptor and glucagon receptor. The company expects to report top-line data from the extended trial in the fourth quarter of 2025.
"By extending exposure to the drug, we aim to more fully evaluate DA-1726’s therapeutic profile across primary, secondary and exploratory endpoints," said Hyung Heon Kim, President and Chief Executive Officer of MetaVia, in a press release statement.
The company reported that previous data from the 32 mg dose demonstrated weight loss effects with a mean of 4.3% and maximum of 6.3% by day 26, along with waist reductions of up to 3.9 inches by day 33.
The Phase 1 trial is a randomized, double-blind, placebo-controlled study investigating safety, tolerability, pharmacokinetics and pharmacodynamics of DA-1726 in obese but otherwise healthy subjects with body mass index between 30-45 kg/m².
The primary endpoint of the trial is to assess safety and tolerability by monitoring adverse events, with secondary endpoints including pharmacokinetics of the drug. Exploratory endpoints include effects on metabolic parameters, cardiac parameters, fasting lipid levels, body weight, waist circumference and body mass index.
MetaVia is also developing DA-1241, a novel G-protein-coupled receptor 119 agonist, for the treatment of Metabolic Dysfunction-Associated Steatohepatitis. With an overall Financial Health Score rated as ’WEAK’ by InvestingPro, investors seeking deeper insights into MetaVia’s financial metrics and growth potential can access 12 additional ProTips and comprehensive analysis through an InvestingPro subscription.
In other recent news, MetaVia Inc. has disclosed that it received a non-compliance notice from Nasdaq. The notice, dated May 29, 2025, indicates that MetaVia’s common stock has not met the minimum bid price requirement of $1.00 per share for 30 consecutive business days, as per Nasdaq Marketplace Rule 5550(a)(2). This development could impact MetaVia’s continued listing on The Nasdaq Capital Market. In another recent development, MetaVia secured approximately $10 million through a private placement. The funds will be directed towards working capital and the clinical development of its obesity treatment, DA-1726. The private placement includes the sale of about 9.5 million shares of common stock at $0.71 each and over 4.6 million pre-funded warrants priced at $0.709 per warrant. These warrants will become exercisable upon stockholder approval for the associated common stock issuance. The transaction is expected to close around May 12, 2025, subject to standard closing conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.